A phase II study of pembrolizumab combination with temozolomide as 1L treatment for Chinese metastatic acral melanoma patients

被引：0
|
作者：
Ding, Y. [1 ]
Xu, Y. [2 ]
Zhang, X. [1 ]
Chen, Y. [2 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Biotherapy, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Fudan Univ, Dept Musculoskeletal Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1131P
引用
收藏
页码：S743 / S743
页数：1
相关论文
共 50 条
  • [1] Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial
    Tas, F
    Argon, A
    Camlica, H
    Topuz, E
    MELANOMA RESEARCH, 2005, 15 (06) : 543 - 548
  • [2] Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.
    Patel, Sapna Pradyuman
    Hwu, Wen-Jen
    Kim, Kevin B.
    Papadopoulos, Nicholas E.
    Hwu, Patrick
    Radvanyi, Laszlo George
    Mahoney, Sandy
    Deburr, Tawania L.
    Liu, Ping
    Bedikian, Agop Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Combination of pembrolizumab (PEMBRO) plus temozolomide (TMZ) therapy in Chinese patients (pts) with advanced acral and mucosal melanoma.
    Hu, Tu
    Sun, Wei
    Xu, Yu
    Luo, Zhiguo
    Chen, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
    Gouda, Mohamed A.
    Stephen, Bettzy
    Tian, Yanyan
    Alshawa, Anas
    Onwugaje, Dilichukwu O. Chudy
    Albittar, Aya
    Yang, Yali
    Zarifa, Abdulrazzak
    Yilmaz, Bulent
    Gurses, Serdar
    Sprenger, Ashabari
    Derbala, Mohamed H.
    Brink, Amanda
    How, Jeffrey Andrew
    Moyers, Justin
    Piha-Paul, Sarina A.
    Hong, David S.
    Meric-Bernstam, Funda
    Patel, Sapna P.
    Oliva, Isabella Glitza
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2024, 7 (04) : 247 - 254
  • [5] Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
    Hwu, WJ
    Krown, SE
    Menell, JH
    Panageas, KS
    Merrell, J
    Lamb, LA
    Williams, LJ
    Quinn, CJ
    Foster, T
    Chapman, PB
    Livingston, PO
    Wolchok, JD
    Houghton, AN
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3351 - 3356
  • [6] PHASE II STUDY OF IPILIMUMAB PLUS TEMOZOLOMIDE IN PATIENTS WITH METASTATIC MELANOMA
    Patel, S.
    Bassett, R.
    Hwu, W.
    Kim, K.
    Papadopoulos, N.
    Hwu, P.
    Bedikian, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 366 - 367
  • [7] A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
    Sapna P. Patel
    Dae Won Kim
    Roland L. Bassett
    Suzanne Cain
    Edwina Washington
    Wen-Jen Hwu
    Kevin B. Kim
    Nicholas E. Papadopoulos
    Jade Homsi
    Patrick Hwu
    Agop Y. Bedikian
    Cancer Immunology, Immunotherapy, 2017, 66 : 1359 - 1366
  • [8] A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
    Patel, Sapna P.
    Kim, Dae Won
    Bassett, Roland L.
    Cain, Suzanne
    Washington, Edwina
    Hwu, Wen-Jen
    Kim, Kevin B.
    Papadopoulos, Nicholas E.
    Homsi, Jade
    Hwu, Patrick
    Bedikian, Agop Y.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (10) : 1359 - 1366
  • [9] Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
    Yao, Yuan
    Yan, Yiyi
    Suman, Vera J.
    Dietz, Allan B.
    Erskine, Courtney L.
    Dimou, Anastasios
    Markovic, Svetomir N.
    Mcwilliams, Robert R.
    Montane, Heather N.
    Block, Matthew S.
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [10] PHASE I STUDY OF THE COMBINATION OF DOCETAXEL, TEMOZOLOMIDE AND CISPLATIN IN PATIENTS WITH METASTATIC MELANOMA
    Kim, K. B.
    Hwu, W. J.
    Papadopoulos, N. E.
    Bedikian, A. Y.
    Camacho, L. H.
    Ng, C.
    Hernandez, I.
    Frost, A. M.
    Jack, M.
    Hwu, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
12345